On the road to developing new therapeutic drugs for osteoporosis and other bone degenerative diseases.
Osteoporosis is a disease that causes bones to fracture easily due to a reduction in both bone mass and quality. Aging is one of its leading causes, and it is estimated that around 200 million people are affected worldwide. Fractures of the femoral neck–the connection between the femur and the hip joint–or of vertebrae can leave a person bedridden which increases the need for care, reduces quality of life and systemic function, and increases mortality.
Bone is a living tissue that is repeatedly broken down (bone resorption) and remade (bone formation) little by little every day. If this balance collapses and bone resorption exceeds bone formation, bone density decreases and can lead to osteoporosis. Several medications are available to treat this disease, but the number of drugs that promote bone formation are far fewer compared to those that suppress bone resorption. The development of therapeutic agents that regenerate bones is highly desired.
Sirtuins are enzymes that play important roles in controlling aging, stress responses, various areas of the metabolism, and several other body functions. In mammals, there are seven types of sirtuins, SIRT1 to SIRT7. Although SIRT7 has been reported to be involved in cancer and lipid metabolism, its role in bone tissue and bone aging was unknown.
1. The effect of SIRT7 on bone formation
Recent experiments performed by a research group led by scientists from Kumamoto University, Japan showed that mice lacking the SIRT7 gene had reduced bone mass. A bone morphometry analysis showed that bone formation and the number of osteoblasts (bone-building cells) had been reduced. Furthermore, the researchers obtained similar results using osteoblast-specific SIRT7 deficient mice, thereby showing that (osteoblast-specific) SIRT7 is important for bone formation.
2. Expression of sirtuins in bone tissue of old mice
Reduced bone formation is common in people with osteoporosis, and the mechanism for this reduction is not well known. To clarify the mechanism, the researchers compared sirtuin (SIRT1, 6, and 7) expression in the skeletal tissue of young and old mice, and found that SIRT7 decreased with age. They then considered that this decrease in SIRT7 in the older specimens may be associated with decreased osteogenesis, and may even be a cause of osteoporosis.
3. The effect of SIRT7 on osteoblast differentiation
When the researchers cultured osteoblasts (in vitro) with decreased SIRT7 expression in their next experiment, the formation of a bone-like mass (calcified nodule) was markedly suppressed compared to cultures of normal osteoblasts. Additionally, the expression of genes indicating osteoblast differentiation was also decreased, thereby revealing that SIRT7 controls the differentiation of osteoblasts.
4. Transcriptional activation of SP7/Osterix by SIRT7
To clarify the mechanism by which osteoblastic SIRT7 positively regulates the differentiation of osteoblasts, researchers investigated the transcription activity of the gene expression regulatory factor essential for osteoblast differentiation. They found that the transcription activity of SP7 (also known as Osterix), a protein known to induce differentiation of pre-osteoblasts into mature osteoblasts and osteocytes, was markedly decreased in osteoblasts that lacked the SIRT7 gene.
They also realized that to get high transcription activation of SP7/Osterix, it is important for SIRT7 to deacylate the 368th lysine residue of the SP7/Osterix protein. In other words, SIRT7 enhances the transcriptional activity of SP7/Osterix by chemically modifying it (deacylating the 368th lysine residue). Furthermore, the researchers were able to recover osteoblast functionality in the calcified nodule formation by introducing a mutant SP7/Osterix, which deacylated the 368th lysine of SP7/Osterix, into the osteoblasts that had reduced SIRT7 expression.
The research group is confident that their results show a new mechanism for SIRT7 as a deacylating enzyme important for transcriptional activation of the gene expression regulator SP7/Osterix and is essential for osteoblast differentiation.
“In situations where SIRT7 does not work sufficiently, such as in an older individual, osteoblast formation is impaired due to low SP7/Osterix transcriptional activity. We believe that this decreased osteogenesis is associated with osteoporosis,” said study leader Dr. Tatsuya Yoshizawa of Kumamoto University. “Our results, show that the regulatory pathway of SIRT7 – SP7 / Osterix is a promising target for new therapeutic agents to treat decreased osteogenesis and osteoporosis.”
The Latest on: Bone degenerative diseases
via Google News
The Latest on: Bone degenerative diseases
- Gene Therapy Is Giving Us Incredible New Tools to Fight Disease. How Far Can It Go?on May 8, 2021 at 6:00 pm
After decades of struggle, we’re finally seeing real-world, life-changing applications right here in Philadelphia. Has medicine finally got gene therapy right?
- SeaSpine Announces Change of Annual Meeting to Virtual Meetingon May 7, 2021 at 1:07 pm
This change does not change the record date for the annual meeting, April 5, 2021, or impact the ability of the Company’s stockholders to vote in advance of the annual meeting by one of the methods ...
- Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritison May 5, 2021 at 4:15 am
Genascence Corporation, a clinical-stage biotechnology company developing life-changing gene therapy products for prevalent musculoskeletal diseases, today announced that dosing across all three ...
- SI-BONE, Inc. Reports First Quarter 2021 Financial Results and Reiterates 2021 Financial Guidanceon May 3, 2021 at 1:03 pm
SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2021.
- Cerapedics’ bone graft gains FDA breakthrough nodon May 3, 2021 at 8:07 am
Cerapedics has won FDA breakthrough device designation for its investigational P-15L bone graft to treat degenerative disc disease.
- US FDA grants Breakthrough Device Designation to Cerapedics’ P-15L Bone Graft to treat degenerative disc diseaseon May 1, 2021 at 2:00 am
US FDA grants Breakthrough Device Designation to Cerapedics’ P-15L Bone Graft to treat degenerative disc disease: Westminster, Colorado Saturday, May 1, 2021, 14:30 Hrs [IST] Ce ...
- Spinal bone graft granted breakthrough device designationon April 30, 2021 at 11:48 am
The FDA has granted breakthrough device designation for Cerapedics' P-15L bone graft for the treatment of degenerative disc disease.
- Cerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Diseaseon April 29, 2021 at 7:01 am
Cerapedics Inc., an ortho-biologics company dedicated to enhancing the science of bone repair, today announced that the U.S. Food and ...
- Pillars of Active Aging - Your Guide To Greens: Vitamins, Minerals, and Health Benefitson April 28, 2021 at 9:00 pm
We all know that eating lots of fruits and vegetables is good for our health, and greens, specifically, have numerous benefits – especially for older adults. Veggies are generally low ...
via Bing News